skip to content


Issue No. 20 | September 13, 2019

News and Features

Updates to the Histoplasmosis Section of the Adult and Adolescent Opportunistic Infections Guidelines

The Histoplasmosis section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV has been updated. The Panel made the following key changes:

  • For both primary and secondary prophylaxis, an undetectable HIV viral load as well as a CD4 count >150 cells/mm3 should be present for 6 months before therapy is stopped in patients taking antiretroviral therapy (ART).
  • For the treatment of patients who do not tolerate itraconazole, voriconazole and posaconazole are discussed in greater detail than before; suggested doses are given, as well as therapeutic serum concentrations that should be sought.
  • Data on the measurement of Histoplasma antigen in serum, urine, bronchoalveolar lavage (BAL) fluid, and cerebrospinal fluid (CSF) is discussed more extensively than previously and has been updated with current terminology using ng/mL instead of units.

September 27 is National Gay Men’s HIV/AIDS Awareness Day

According to the Centers for Disease Control and Prevention (CDC), gay and bisexual men are the population most affected by HIV in the United States. In 2016, gay and bisexual men accounted for 67% of the 40,324 new HIV diagnoses in the United States and six dependent areas.

National Gay Men’s HIV/AIDS Awareness Day is observed each year to focus attention on the disproportionate impact of HIV/AIDS on gay and bisexual men. To learn more, visit the AIDSinfo National Gay Men’s HIV/AIDS Awareness Day webpage [en español].